5-(N,N-dimethyl)-Amiloride (hydrochloride): Benchmarking a Selective NHE1 Inhibitor for Ion Transport and Cardiovascular Research

Executive Summary: 5-(N,N-dimethyl)-Amiloride (hydrochloride) is a crystalline small molecule that selectively inhibits Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3, with Ki values of 0.02 µM, 0.25 µM, and 14 µM, respectively (APExBIO). It disrupts intracellular pH regulation and sodium transport, allowing mechanistic dissection of cardiovascular and endothelial signaling pathways (Chen et al., 2021). The compound is highly soluble in DMSO (up to 30 mg/ml), supporting diverse experimental applications. Its protective effects against ischemia-reperfusion injury and cardiac contractile dysfunction have been validated in preclinical models (Related Article). APExBIO’s C3505 is intended for research use only and is not suitable for diagnostic or therapeutic applications.

Biological Rationale

The Na+/H+ exchanger (NHE) family regulates intracellular pH and sodium balance in mammalian cells. NHE1, the predominant isoform in cardiac and vascular tissues, is essential for cell volume regulation and pH homeostasis. Abnormal NHE1 activation contributes to pathologies such as ischemia-reperfusion injury, sepsis-induced endothelial dysfunction, and cardiac contractile failure (Chen et al., 2021). Selective inhibition of NHE1 is a critical experimental strategy for delineating ion transport pathways and their roles in disease models. 5-(N,N-dimethyl)-Amiloride (hydrochloride) acts as a reference compound in studies of cardiovascular disease, endothelial injury, and metabolic regulation.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

5-(N,N-dimethyl)-Amiloride (hydrochloride) is a structural analog of amiloride, engineered for increased potency and isoform selectivity. The compound binds to the extracellular region of NHE1, NHE2, and NHE3, competitively inhibiting sodium influx and proton extrusion. This inhibition disrupts the Na+/H+ gradient, lowering intracellular pH and altering sodium-dependent cellular processes. DMA’s selectivity profile is characterized by negligible activity against NHE4, NHE5, and NHE7 at experimental concentrations (APExBIO). Mechanistically, DMA also inhibits ouabain-sensitive ATP hydrolysis and Na+/K+ ATPase activity, and reduces alanine uptake in hepatocytes, reflecting broader effects on sodium-driven transport and metabolism (Related Article).

Evidence & Benchmarks

• DMA exhibits a Ki of 0.02 µM for NHE1, 0.25 µM for NHE2, and 14 µM for NHE3, confirming potent and selective inhibition (APExBIO).
• In ex vivo cardiac models, DMA normalizes sodium levels and prevents contractile dysfunction following ischemia-reperfusion injury (Related Article).
• DMA reduces ouabain-sensitive ATPase activity in rat liver plasma membranes, implicating effects beyond NHE inhibition (Related Article).
• In endothelial injury models, NHE1 inhibition mitigates cytoskeletal rearrangement and inflammatory signaling via reduced Rock1/MLC and NF-κB activation (Chen et al., 2021).
• DMA’s solubility reaches 30 mg/ml in DMSO or DMF, supporting high-throughput screening and in vivo administration (APExBIO).

Applications, Limits & Misconceptions

DMA is widely used in:

• Cardiovascular research, particularly ischemia-reperfusion injury and contractile dysfunction models.
• Studies of intracellular pH regulation and sodium-coupled transport.
• Endothelial injury, sepsis, and inflammation signaling pathway dissection.
• Metabolic flux analysis in hepatocytes and other cell types.

This article clarifies mechanistic details and expands upon the workflow guidelines provided in this benchmarking guide, by presenting new evidence from sepsis and endothelial injury models. For a translational focus on biomarker-driven strategies, see this review, which this dossier updates with more quantitative selectivity and workflow recommendations.

Common Pitfalls or Misconceptions

• DMA is not suitable for diagnostic or therapeutic use in humans; it is for research use only (APExBIO).
• Long-term storage of DMA solutions is not recommended; solutions should be prepared fresh and used promptly.
• DMA does not effectively inhibit NHE4, NHE5, or NHE7 at standard concentrations.
• Observed effects on ATPase activity and alanine uptake may reflect off-target actions and should be interpreted with appropriate controls.
• DMA’s effects are highly context-dependent; results in hepatic cells may not directly translate to cardiac or endothelial systems.

Workflow Integration & Parameters

To integrate 5-(N,N-dimethyl)-Amiloride (hydrochloride) into experimental workflows:

• Prepare DMA stock solutions up to 30 mg/ml in DMSO or DMF; dilute into physiological buffer for cell-based assays.
• Store powder at -20°C; avoid repeated freeze-thaw cycles.
• Select concentrations based on target isoform affinity (e.g., ≤0.1 µM for NHE1-specific inhibition).
• Include vehicle controls to account for solvent effects.
• Combine with functional readouts (e.g., pH-sensitive dyes, sodium flux assays, contractility measurements).

The C3505 kit from APExBIO provides validated product specifications for these applications.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) is an established, highly selective NHE1 inhibitor that advances research into ion transport, pH regulation, and cardiovascular pathology. Its benchmarked selectivity and robust solubility profile make it suitable for high-fidelity mechanistic studies. Future research may leverage DMA for discovery of new biomarkers and therapeutic targets in cardiovascular and inflammatory diseases. For further mechanistic context and experimental strategies, see this recent update, which this dossier extends by integrating recent biomarker and workflow insights.